Drugs approved by the Food and Drug Administration (FDA) for HNSCC treatment include chemotherapeutic agents (cisplatin, 5-fluorouracil, methotrexate, and docetaxel), epidermal growth factor receptor (EGFR) inhibitor Cetuximab and immune checkpoint inhibitors (Nivolumab and Pembrolizumab) [3]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.